Tempest Therapeutics
Pioneering the future of cancer treatment with innovative small molecule therapeutics that enhance anti-tumor immunity.
Pioneering the future of cancer treatment with innovative small molecule therapeutics that enhance anti-tumor immunity.
Tempest Therapeutics is a San Francisco-based biotechnology startup founded in 2011. The company is focused on pioneering the future of cancer treatment through innovative small molecule therapeutics that enhance anti-tumor immunity. Tempest Therapeutics has garnered attention due to its balanced and extensive pipeline, featuring first-in-class and best-in-class small molecule therapeutics targeting distinct pathways crucial for an effective anti-tumor response. Their last investment of $15.00M in post-IPO equity came on 27 April 2022, with backing from Versant Ventures and EcoR1 Capital. Specializing in the biotechnology and health care industries, Tempest Therapeutics continues to be a key player in the development of novel cancer treatment solutions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $15.00M | 2 |
|
27 Apr 2022 |
| Series B | $70.00M | 6 |
|
28 Mar 2018 |
| Venture Round | $5.00M | - | 05 Oct 2011 |
No recent news or press coverage available for Tempest Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
